Forte Biosciences (FBRX) Other financing activities (2020 - 2026)
Forte Biosciences (FBRX) posted quarterly Other financing activities of $101000.0 for Q1 2026, up 1022.22% year-over-year from $9000.0 in Q1 2025, and up 531.25% quarter-over-quarter from $16000.0 in Q3 2025.
Forte Biosciences (FBRX) Other financing activities (2020 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Other financing activities for 7 consecutive years, with $101000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 1022.22% year-over-year to $101000.0; the TTM figure through Mar 2026 stood at $110000.0 (down 90.2% YoY), while the FY2025 annual figure was $18000.0, down 98.39% from the prior year.
- Other financing activities rose to $101000.0 in Q1 2026 per FBRX's latest filing, from $16000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $1.1 million in Q4 2024 and bottomed at -$8000.0 in Q3 2024.
- Historically, Other financing activities has averaged $165300.0 across 5 years, with a median of $31000.0 in 2022.
- Annual changes were most pronounced in 2025 — Other financing activities gained 12.5% — and 2026, when it surged 1022.22%.
- Forte Biosciences' Other financing activities stood at $110000.0 in 2022, then surged by 133.64% to $257000.0 in 2023, then surged by 336.19% to $1.1 million in 2024, then plunged by 98.57% to $16000.0 in 2025, then jumped by 531.25% to $101000.0 in 2026.
- Business Quant data shows FBRX's Other financing activities at $101000.0 in Q1 2026, $16000.0 in Q3 2025, and -$7000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.40 Mn |
| Jun 30, 2026 | 22.40 Mn |
| Mar 31, 2026 | 101,000.00 |
| Mar 31, 2026 | 101,000.00 |
| Sep 30, 2025 | 16,000.00 |
| Sep 30, 2025 | 16,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Dec 31, 2024 | 1.12 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | -8,000.00 |
| Sep 30, 2024 | -8,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Dec 31, 2023 | 257,000.00 |
| Dec 31, 2023 | 257,000.00 |
| Jun 30, 2022 | 110,000.00 |
| Jun 30, 2022 | 110,000.00 |